Management of renal osteodystrophy with 1,25(OH)2D3. II. Effects on histopathology of bone: Evidence for healing of osteomalacia

H. H. Malluche; D. A. Goldstein; S. G. Massry

Management of renal osteodystrophy with 1,25(OH)₂D₃. II. Effects on histopathology of bone: Evidence for healing of osteomalacia

H. H. Malluche, D. A. Goldstein, S. G. Massry

Internal Medicine

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

The effects of 6 months of therapy with 1,25(OH)₂D₃ on bone histology were evaluated in 12 dialysis patients. They all displayed evidence of bone disease consisting of osteitis fibrosa and osteomalacia of varying degrees and predominance. Therapy with 1,25-(OH)₂D₃ was associated with: decrease in osteoclastic activity; reduction or disappearance of endosteal fibrosis; - this improvement was independent of changes in serum iPTH levels; decrease in woven osteoid; decrease or normalization of osteoid volume, and normalization of bone mineralization. The data indicate that long-term therapy with 1,25(OH)₂D₃ can improve hyperparathyroid bone disease, restore bone architecture and heal osteomalacia.

Original language	English
Pages (from-to)	48-55
Number of pages	8
Journal	Mineral and Electrolyte Metabolism
Volume	2
Issue number	1
State	Published - 1979

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Biochemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{95635687870e49b888e30c306613277e,

title = "Management of renal osteodystrophy with 1,25(OH)2D3. II. Effects on histopathology of bone: Evidence for healing of osteomalacia",

abstract = "The effects of 6 months of therapy with 1,25(OH)2D3 on bone histology were evaluated in 12 dialysis patients. They all displayed evidence of bone disease consisting of osteitis fibrosa and osteomalacia of varying degrees and predominance. Therapy with 1,25-(OH)2D3 was associated with: decrease in osteoclastic activity; reduction or disappearance of endosteal fibrosis; - this improvement was independent of changes in serum iPTH levels; decrease in woven osteoid; decrease or normalization of osteoid volume, and normalization of bone mineralization. The data indicate that long-term therapy with 1,25(OH)2D3 can improve hyperparathyroid bone disease, restore bone architecture and heal osteomalacia.",

author = "Malluche, {H. H.} and Goldstein, {D. A.} and Massry, {S. G.}",

year = "1979",

language = "English",

volume = "2",

pages = "48--55",

number = "1",

}

TY - JOUR

T1 - Management of renal osteodystrophy with 1,25(OH)2D3. II. Effects on histopathology of bone

T2 - Evidence for healing of osteomalacia

AU - Malluche, H. H.

AU - Goldstein, D. A.

AU - Massry, S. G.

PY - 1979

Y1 - 1979

N2 - The effects of 6 months of therapy with 1,25(OH)2D3 on bone histology were evaluated in 12 dialysis patients. They all displayed evidence of bone disease consisting of osteitis fibrosa and osteomalacia of varying degrees and predominance. Therapy with 1,25-(OH)2D3 was associated with: decrease in osteoclastic activity; reduction or disappearance of endosteal fibrosis; - this improvement was independent of changes in serum iPTH levels; decrease in woven osteoid; decrease or normalization of osteoid volume, and normalization of bone mineralization. The data indicate that long-term therapy with 1,25(OH)2D3 can improve hyperparathyroid bone disease, restore bone architecture and heal osteomalacia.

AB - The effects of 6 months of therapy with 1,25(OH)2D3 on bone histology were evaluated in 12 dialysis patients. They all displayed evidence of bone disease consisting of osteitis fibrosa and osteomalacia of varying degrees and predominance. Therapy with 1,25-(OH)2D3 was associated with: decrease in osteoclastic activity; reduction or disappearance of endosteal fibrosis; - this improvement was independent of changes in serum iPTH levels; decrease in woven osteoid; decrease or normalization of osteoid volume, and normalization of bone mineralization. The data indicate that long-term therapy with 1,25(OH)2D3 can improve hyperparathyroid bone disease, restore bone architecture and heal osteomalacia.

UR - http://www.scopus.com/inward/record.url?scp=0018763813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018763813&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0018763813

VL - 2

SP - 48

EP - 55

IS - 1

ER -

Management of renal osteodystrophy with 1,25(OH)₂D₃. II. Effects on histopathology of bone: Evidence for healing of osteomalacia

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this